Infectious Diseases News

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (TSX: COV; OTCQX: CVALF), an advanced medical technologies company, today announced a series of important milestones reflecting the Company's growing market development and commercial momentum, and deepening engagement across the vascular access, infection prevention, and wound care sectors. Strong Engagement at Infusion Nurses Society Annual Meeting Covalon had a strong presence at the Infusion Nurses Society (INS) Annual Meeting...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa™ HD / Epioxa™ (“Epioxa”) for the treatment of keratoconus, a rare, sight-threatening disease...

WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Eradivir Inc., a clinical-stage biotech company developing antibody-recruiting small molecules to treat disease, today announced it will deliver oral presentations at ESCMID Global 2026 and at the International Conference on Antiviral Research (ICAR) 2026, highlighting clinical and preclinical data across its influenza and respiratory syncytial virus (RSV) programs. At the two international scientific meetings, Eradivir will present data from its lead infl...

PARIS--(BUSINESS WIRE)--Enodia Therapeutics, a biotechnology company developing small-molecule therapies targeting a unique form of protein degradation at the point of synthesis, appointed Yvonne McGrath, Ph.D. as Chief Scientific Officer. With over 25 years of experience in biopharma drug development and life sciences, Dr. McGrath will help optimize Enodia’s proprietary platform, which is designed to discover and develop small-molecule therapies that enable the selective degradation of protein...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received Clinical Trial Application (CTA) approval to expand the ongoing global ELIMINATE-B clinical trial of PBGENE-HBV. The regulatory authorization will allow Precision to initiate important hepatitis B clinical trial sites in France a...

NEWCASTLE, England--(BUSINESS WIRE)--Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced it has established a strategic partnership with JH Health Ltd, a Saudi Arabian company focused on medical and health-related technology. The partnership grants JH Health exclusive rights to use and distribute Atelerix’s hydrogel-based cell and tissue preservation solutions in the Middle East, significan...

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma will present 10 studies on Nacubactam at ESCMID Global 2026 including Phase III Integral-2 results in patients with CRE infections....

HILDEN, Germany & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel. The launch of this new QIAstat-Dx panel coincides with the ESCMID Global 2026 Congress in Munich (April 17–21), where QIAGEN will highlight its broad infectious disease portfolio, including QIAstat-Dx, the QuantiFERON-TB Gold Plus...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. State Department, the United States President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead’s twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028. Bringing together th...

LOS ANGELES--(BUSINESS WIRE)--Sutter Health is expanding the use of FloPatch, the first wireless, wearable Doppler ultrasound device, across three additional Northern California hospitals: Sutter Solano Medical Center in Vallejo, Sutter’s Mills-Peninsula Medical Center in Burlingame and the Berkeley campus of Sutter’s Alta Bates Summit Medical Center, as part of its ongoing effort to enhance personalized intravenous (IV) fluid management for patients with sepsis and other life-threatening condi...